HALISTER1: Aptose Biosciences Rises; HC Wainwright Sees Inflection Point

Aptose Biosciences Rises; HC Wainwright Sees Inflection Point

(Bloomberg) -- Aptose Biosciences rises 8% pre-market on 2.6k volume after HC Wainwright upgraded to buy from neutral, PT $4 from $1.
  • Says co. made progress on the manufacturing process for CG’806 and is targeting the initiation of toxicology studies shortly
  • Says an IND filing is targeted for 1H 2018, assuming clean toxicology studies, with the initiation of the clinical programs soon after that
  • Notes the Ash conf. in December should provide more visibility on CG’806
  • NOTE: Jan. 23, Aptose Pauses APTO-253 Development, Will Prioritize CG’806
To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Steven Fromm

Alert: HALISTER1
Source: BFW (Bloomberg First Word)

Tickers
APS CN (Aptose Biosciences Inc)

To de-activate this alert, click here
To modify this alert, click here

UUID: 7947283